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Abstract We have previously reported the crystal structure of truncated human collagenase (domain II) complexed with a low molecular weight 
inhibitor. Attempts to crystallise full-length active collagenase (i.e. domain II + III) have been hindered by autoproteolysis at the domain II/III junction 
at high protein concentrations. Toovercome this problem, we have generated an inactive nzyme via a H149-1 L,D151 +N double substitution which 
displaces the non-catalytic zinc atom, and shown that the altered collagenase is unable to cleave a synthetic substrate. We have also generated an 
1251 +S substitution at the domain II/III junction and demonstrate anincreased resistance toproteolysis compared to wild-type collagenase. 
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1. Introduction 
Metalloproteinases (MMPs) play a pivotal role in the degra- 
dation of connective tissue matrices which is the basis of tissue 
remodelling and cellular trafficking. Under pathological condi- 
tions, MMPs are instrumental in tumour invasiveness during 
metastasis and cartilage destruction during arthritis. They rep- 
resent members of a gene family which includes fibroblast col- 
lagenase [l], neutrophil collagenase [2], gelatinases [3,4], 
stromelysins I, II, III [5-71, and pump-l [5]. Sequence compar- 
ison and functional analysis of the MMPs has revealed the 
presence of individual domains within the protein which give 
the MMPs characteristic properties. Domain I (l-82 aa) in- 
cludes the signal sequence and pro-peptide which contains the 
conserved sequence PRCGVPD. This sequence maintains la- 
tency of the secreted pro-enzyme via a ‘cysteine switch’ [8,9]. 
Domain II (83-250 aa) includes the active site [lo] and the 
catalytic Zn” binding region (VAAHELGHSLG). The C-ter- 
minal domain III, homologous to hemopexin, has been less- 
well character&d, but may function as part of the binding site 
for natural inhibitors such as TIMP [5,10]. Furthermore, it has 
been proposed that domain III imposes substrate specificity 
upon the active site in domain II [8]. The key to understanding 
the basis of different substrate specificities of the MMP family 
members lies in the detailed knowledge of the interaction be- 
tween domains II and III. We have therefore attempted to 
crystallise full-length active human collagenase (domain 
II+ III) but have been hindered by autoproteolysis at 
the domain II/III junction. To avoid this problem, we have 
altered the likely target peptide bond in this region. 
We have also investigated the function of the second non- 
catalytic zinc atom [l 11, which has been confirmed in the crystal 
structure of collagenase domain II [12,13]. Analysis of the 
structure revealed the chelating groups to be H 149, D15 1, H164 
and H177. Thus we have substituted H149 to leucine 
(H149+L) and D151 to asparagine (D151-+N) to 
generate a double-substituted collagenase designed to be de- 
pleted of the second zinc. 
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2. Materials and methods 
2.1. Generation of wild-type and mutated collagenase cDNA expression 
constructs 
A 1.4 kb partial Xbal fragment of collagenase cDNA (bp 136-l 567, 
see [l]) was blunted by end-filling using Klenow polymerase and cloned 
into a Smal site previously incorporated in the expression vector 
pDS56RBSII-6HIS [14]. This construct is designated pHCOL, and 
encodes procollagenase. The collagenase domain II was generated via 
PCR using the oligonucleotides S’CTCACAGGGATCCAGCGACT- 
CTAGAAACACAA-Y and S-GTITGTGAAGCTTAGGGCTGG- 
ACAGGATTITGGGA-3’ as 5’ and 3’ primers, respectively, upon 
pHCOL DNA as a template, and the resulting domain II-encoding 
DNA was cloned into the BamHl site of pDS56RBSII-6HIS. This 
construct was designated pTCOL. PCR conditions using Vent polym- 
erase were as recommended by the supplier (New England Biolabs). 
Site-directed mutagenesis was performed on Ml 3mplS-pHCOL single- 
stranded DNA using Muta-Gene kit (Stratagene) using mismatched 
primers. 
2.2. Isolation and purification of N-terminal hexahistidine-tagged 
proteins 
200 ml cultures of pHCOL or pTCOL in JM103 were grown up 
overnight at 37°C in M9 + 50 pg ampicillin + 1 pg thiamine. Each cul- 
ture was used to inoculate 800 ml Luria broth + 50 pg ampicillin. IPTG 
was added at a broth optical density OD,, nm of 0.60.8 to a concentra- 
tion of 2 mM, and bacteria were harvested 4 h later by centrifugation. 
The bacteria were lysed and proteins denatured by resuspension and 
stirring for 1 h in 6 M guanidine hydrochloride, 0.1 M NaH,PO.,, pH 
8.0. The cleared lysate was loaded onto a Ni’+-NTA agarose column. 
Washing was performed using 6 M guanidine hydrochloride, 0.1 M 
NaH2P04, pH 8.0, then 8 M urea, 0.1 M NaH*PG,, 0.01 M Tris-HCl, 
pH 7.5, to remove non-specifically bound protein. Renaturation of 
protein was performed on the column using 2 M urea, 0.1 M NaH$Q, 
0.01 M Tris-HCI, pH 7.5, followed by 0.2 M NaCl, 50 mM Tris-HCl, 
2 mM CaCl,, pH 7.4. Bound protein was eluted from the column using 
0.5 M imidazole, 0.2 M NaCl, 50 mM Tris-HCl, 2 mM CaCI,, pH 7.4. 
The purified protein was then dialysed extensively against 0.2 M NaCl, 
50 mM Tris-HCl, 2 mM CaCl,, pH 7.4. 
2.3. Isolation of activated recombinant collagenase 
Purified non-activated TCOL (domains I + II: aa 2@270 of collage- 
nase as in [l], plus N-terminal hexahistidine tag) or HCOL (domains 
I + II + III: aa 20 to C-terminus of collagenase as in [l], plus N-terminal 
hexahistidine tag), was treated with 40pg/ml trypsin for 50min at 37°C. 
This protein solution was then passed twice down a soya bean trypsin 
inhibitor agarose column to remove contaminating trypsin. The protein 
was then precipitated at 4’C at 80% ammonium sulphate and dissolved 
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in 0.2 M NaCI, 50 mM Tris-HCl, 2 mM CaCl,, pH 7.4, to a concentra- 
tion of approximately 1mg/ml. This solution was then dialysed against 
the same buffer. Further protein concentration was performed using 
10 kDa cut-off ultraconcentrators (Amicon). 
2.4. Synthetic hexapeptide assay 
This is a modified version of the assay described in [15] using the 
substrate Ac-Pro-Gln-Gly-Leu-Leu-Gly-OEt. Briefly, 0.5 mM sub- 
strate was incubated with purified enzyme at 37°C for between 2 and 
16 h in 50 mM boric acid (pH 7.4), 1 mM CaCl,. A further 37°C 
incubation was performed, for 1 h, after the addition of 1% pic- 
rylsulphonic acid in 2% w/v sodium bicarbonate dissolved in aqueous 
50% methanol. 1 M HCl was added and spectrophotometric readings 
taken 20 min later at 335 nm to monitor the amount of trinitrophenyl 
peptide formed. 
2.5. Collagen jibril assay 
“‘C-Labelled collagen was dried to a film, in 96-well microtitre plates, 
from thermally reconstituted fibrils [16]. 200 ~1 samples of purified 
enzyme in 0.2 M NaCl, 50 mM Tris-HCl @H 7.4), 2 mM CaCl,, were 
incubated in the microtitre wells for 8 h at 37°C. The amount of 14C 
in the supernatant, representing soluble collagen degradation products, 
was measured by scintillation counting. An excess of bacterial collage- 
nase was used to determine the maximum amount of degradation under 
these conditions. 
2.6. Mass spectrometry analysis 
HCOL (10 mg/ml) and HCOL 1251+S (17 mg/ml) were mixed with 
an equal volume of sinapinic acid and analysed on a FinneganMat 
MALDI. 
3. Results and discussion 
3.1. Recombinant procollagenase undergoes autoproteolysis 
Human procollagenase cDNA was sub-cloned into the hex- 
ahistidine-tagged expression vector pDS56RBSII-6HIS. Subse- 
quent expression and purification of the recombinant collage- 
nase from E. coli produced variable amounts of a 52 kDa 
protein (consistent with the size of procollagenase), and an 
abundant 46 kDa protein, consistent with the size of collage- 
nase activated by autoproteolysis (Fig. lA, lane 2). When these 
purified preparations of human collagenase are stored at 4°C 
at >O. 1 mg/ml for a few weeks, further autoproteolysis occurs. 
The derived products represent domain III (approx 26 kDa) 
and domain II (approx 20 kDa) (Fig. lB, compare lanes 4 and 
6). Previous reports using N-terminal amino acid sequencing 
have revealed that P250-1251 is the likely cleavage site in acti- 
vated collagenase [lo], although this has yet to be confirmed by 
site-directed mutagenesis. In addition, previous reports have 
also shown that a collagenase(domain II)-stromelysin 2(do- 
main III) chimera shows limited autoproteolysis [17]. Inspec- 
tion of the domain II-III junction sequences shows that strome- 
lysin 2 contains a serine at the corresponding position of 1251 
in collagenase (Fig. 2a). We therefore generated an 1251 -+S 
substitution in recombinant collagenase to investigate whether 
this would increase resistance to proteolysis and facilitate the 
purification of full-length activated enzyme. It was found that, 
as expected, the substitution does not alter the collagenolytic 
properties of the enzyme (data not shown). After prolonged 
storage at 4”C, the 125 1 + S-substituted collagenase was more 
resistant to proteolysis than the wild-type enzyme (Fig. lB, 
compare lanes 4 and 5). We investigated the limited degrada- 
tion which had taken place in the 1251 -+S variant to check 
whether a shift to an alternative cleavage site had occurred to 
generate similar sized products. Mass spectrometry measure- 
ments revealed predominant degradation products of 
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Fig. 1. (A) SDS-PAGE gel stained with Coomassie blue showing freshly 
purified wild-type (lane 2) and 1251+ S mutant (lane 3) recombinant 
collagenase. (B) Similar gel showing wild-type (lane 4) and 1251 +S 
mutant (lane 5) collagenase after storage at 4°C compared with trun- 
cated (83-250 aa) collagenase which constitutes domain II (lane 6). 
(C) Scheme showing molecular weights of collagenase domains as cal- 
culated on Wisconsin GCG software. 
23,690 f 47 and 18,826 f 38 Da for wild-type collagenase, and 
23,671 f 47 and 18,796 + 38 Da for the 1251+ S variant (data 
not shown). The similarity in these molecular weights suggests 
that the 1251-+ S substitution has not induced a shift to an 
alternative cleavage site, therefore the collagenase active site 
can accommodate a serine at Pl’ instead of isoleucine, albeit 
with lower efficiency. We note that only human fibroblast col- 
lagenase has the target P250-1251 peptide bond at the domain 
II-III junction (Fig. 2a). It would be interesting to investigate 
whether such autoproteolysis occurs in vivo as a protective 
autoregulatory mechanism to avoid excessive collagen fibril 
damage in pathological conditions. Thus, over-production of 
fibroblast collagenase would result in a separation of domain 
II from domain III and therefore loss of collagen specificity. 
This would sustain collagen fibril levels and change the specific- 
ity of the activated truncated collagenases toward denatured 
collagenous fragments [lo]. Clearly, the proposed autoregula- 
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neutro. co11 IQ........ ..PTGPSTP. . . . . . . ..KP CDPSLTFDAI TTLRGEILFF 
fibro. co11 VQ........ ..PzGPQTP. . . . . . . ..KA CDSKLTFDAI TTIRGEVMFF 
stromelysin 1 PETPLVPTE PVPPEPGTP. .._... ..AN CDPALSFDAV STLRGEILIF 
stromelysin 2 TEEPLVPTK SVPSGSEMP. . . . . . . ..AK CDPALSFDAI STLRGEYLFF 
rat co11 PN........ ..PKHPKTP. . . . . . . ..EK CDPALSLDAI TSLRGETMIF 
72kd gelatinase LGTGPT. PTLGPVTP. ..EI CKQDIVFDGI AQIRGEIFFF 
95kd gelatinase TGPPSAGPTG PPTAGPSTAT &L&DDA ~N~NI.FDAI AEIGNQLYLF 
Consensus __________ __p-G---p_ -___-__--_ CD--L-FDAI _T_RGE_L-F 
b 
neutro. co11 TRISQGEADI NIAFYQRDHG ENSPFDGPNG ILAEAFQPGQ GIGGDMFDA 
fibro. co11 TKVSEGQADI MISFVRGDBR ENSPFDGPGG NLAHAFQPGP GIGGDA&FDE 
stromelysin 1 SRLYEGEADI MISFAVREHG DFYPFDGPGN VLAmYAPGP GINGDMFDD 
stromelysin 2 SRLYEGEADI MISFAVKEEG DFYSFDGPGH SLWYPPGP GLYGDIBFDD 
rat co11 TRIHDGTADI MISFGTKEHG PFYPFDGPSG LLqH_FPPGP NLGGDm_FDD 
stromelysin 3 TEVHEGRADI MIDFARm DDLPFDGPGG ILMAFFPKT HREGDV&FDY 
72kd gelatinase SRIHDGEADI MINFGRWEHG SYPFDGKDG LLUAFAPGT GVGGDSBFDD 
95kd gelatinase TRVYSRDADI VIQFGVAEHG =YPFDGKDG LLABAFPPGP GIQGDWFDD 
Consensus ----EG-AD1 MI-F---EHG D--PFDGP-- -LAHAF-PG- ---GD-IiFD- 
Fig. 2. Sequence homologies between MMPs using PILEUP on Wisconsin GCG software showing sequence comparison of (a) domain II and III 
junction, and (h)chelating residues for non-catalytic zinc atom. The relevant amino acids discussed in the text are highlighted in bold-type. 
tory mechanism would act in concert with trans-regulatory 
protease systems, utilising stromelysin and uPA, which also 
exert fine control over active collagenolytic activity. 
3.2. Effect of H149+L,DISl+ N site-directed mutagenesis 
Crystallographic studies have revealed a second zinc in the 
collagenase molecule. The sequence comparison in Fig. 2b 
shows that the residues involved in the coordination complex 
are highly conserved throughout the MMP family. We have 
introduced a H149+L,D151 +N double substitution in 
HCOL and thus have presumably depleted collagenase specifi- 
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Fig. 3. Comparison of proteolytic activities of 1251 +S (v) and 
H149+ L,D151 -+N mutant (v) collagenases using a hexapeptide sub- 
strate. 
tally of the second zinc. Fig. 3 shows that this results in a 
dramatic loss of proteolytic activity compared to 1251 +S 
HCOL. This inactivity is not due to collapse of secondary 
structure since the CD spectra of the inactive and active vari- 
ants demonstrates a fairly small difference, with a slight appar- 
ent increase in the a-helix content of the inactive form (Fig. 4). 
Therefore, the inactivity is due to relatively small perturbations 
in secondary structure, mediated by the displaced H149 and 
D151 chelating residues. This suggests that the second zinc 
atom is not fundamentally important for the maintenance of 
the tertiary structure of collagenase. The four chelating residues 
are nevertheless trongly conserved across the MMP family, 
and our observation suggests that they are crucial for catalytic 
activity. Thus we would hypothesise that the second zinc atom 
plays a major role in defining the local environment of the 
active site. We cannot, as yet, define the molecular details of 
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Fig. 4. CD spectra of 1251 +S collagenase in water (a) and 50% 
trifluroethanol (c), and H 149 + L,D 15 1 + N collagenase in either water 
(b) or 50% trifluroethanol (d) using a Jasco J-600 spectrophotometer. 
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this role, but we would speculate that the second zinc atom is 
instrumental in fixing the position of an exposed loop (aa 146 
162) which may have medium-range effects (approximately 
12 A) upon the position of the catalytic helix. 
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